Navigation Links
Interleukin Genetics to Present Research Findings at Upcoming Medical Meetings
Date:10/13/2009

WALTHAM, Mass., Oct. 13 /PRNewswire-FirstCall/ -- Interleukin Genetics, Inc. (NYSE Amex: ILI) announced today it will present new genetic findings in the fields of obesity and osteoporosis at medical meetings later this month. The Company will also exhibit at the American Dietetic Association's (ADA) Food and Nutrition Conference & Expo in Denver, Colo.

Specific presentation details are as follows:

IDF 20th World Diabetes Congress - Montreal, Canada.

Date: October 20, 2009

Time: 1-2 p.m.

Interleukin Genetics will present a poster titled, "Perilipin, IL-1, ADRB and MCR-4 Gene Variants Identify Bariatric Surgery Patients who are Predisposed to Dyslipidemia," at the poster discussion session entitled Complications-dyslipidemia. The poster, #D-0809, will highlight findings that suggest genetic polymorphisms in the perilipin, IL-1, ADRB and MCR-4 genes may predispose to abnormal levels of blood lipids and therefore could have clinical utility in the management of obese patients.

American Society of Human Genetics 59th Annual Meeting - Honolulu, HI

Date: October, 21, 2009

Time: 1-2 p.m.

Interleukin Genetics will present a poster titled, "A Polymorphism in the IL1-B Gene is Associated with Vertebral Fracture Independent of Bone Mineral Density." The poster, #369, will highlight findings that suggest variations in the IL1B, VDR, and ESR1 genes may indicate susceptibility for vertebral fracture or low bone mineral density. These findings should be valuable in guiding medical management of osteoporosis, design of clinical trials of investigational new drugs, as well as guiding preventive treatments for individuals at risk for the disease.

Obesity Society 27th Annual Scientific Meeting - Washington, D.C.

Date: October, 25, 2009

Time: 1-7:30 p.m.

Interleukin Genetics will present a poster titled, "Perilipin, IL-1 and ADRB Gene Variants Identify Bariatric Surgery Patients who are Resistant to Weight Loss under Calorie Restriction in Preoperative Weight Loss Program." The poster, #322-P, highlights findings which suggest that genetic polymorphisms in perilipin, IL-1 and ADRB genes show strong association with resistance to weight loss under caloric restriction. These genetic risk markers could have important clinical utility in the medical management of obese patients and in the design of optimal weight loss programs.

In addition to the scientific presentations, Interleukin Genetics will exhibit at the following conference.

American Dietetic Association FNCE Meeting - Denver, CO

Date: October 17-20, 2009

Booth #1900

Interleukin Genetics will exhibit at the ADA's annual Food and Nutrition Conference & Expo, which will demonstrate the latest nutrition science information and foodservice trends. Highlighted at the Company's Booth will be the new Inherent Health((TM)) Weight Management Genetic Test designed to guide optimal diet and exercise regimens based on genetics.

About Interleukin Genetics

Interleukin Genetics, Inc. (NYSE Amex: ILI) develops and markets genetic tests under the Inherent Health(TM) brand that empower consumers to prevent chronic diseases of aging, and provides genetic biomarker expertise to assist pharmaceutical companies in the development and marketing of targeted therapeutics. The Company leverages its research, intellectual property and biomarker development experience to facilitate the emerging personalized health market. Interleukin Genetics is headquartered in Waltham, MA. For more information please visit www.ilgenetics.com.

SOURCE Interleukin Genetics, Inc.


'/>"/>
SOURCE Interleukin Genetics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Interleukin Genetics Announces Strategic Divestment of Alan James Group
2. Interleukin Genetics Launches Inherent Health Brand of Genetic Tests Offering Clear and Personalized Insights to Wellness
3. Interleukin Genetics to Present Research Linking Perilipin Genes to Diet Response at the ADA Annual Meeting
4. Interleukin Genetics Reports First Quarter 2009 Financial Results
5. NYSE Amex Accepts Interleukin Genetics Plan to Meet Continued Listing Standards
6. Interleukin Genetics to Chair Expert Panel Discussion on Use of Biomarkers in Drug Development at BIO Convention
7. Interleukin Genetics Announces Conference Call to Discuss First Quarter 2009 Results
8. Interleukin Genetics Grants LABEC Pharma a License for Sales and Distribution of Its Heart Health Genetic Test
9. Interleukin Genetics Receives NYSE Amex Staff Determination, Requests Oral Hearing Before the Listing Qualifications Panel
10. Interleukin Genetics Announces Conference Call to Discuss Fourth Quarter 2008 Results
11. Interleukin Genetics to Present at G-2 Reports Molecular Diagnostic Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/5/2016)... ... December 05, 2016 , ... Worldwise ®, a ... design firm kathy ireland® Worldwide for five additional years, announced by Kevin Fick, ... exclusive licensing agreement three years ago to design and develop the kathy ireland® ...
(Date:12/5/2016)... St. Louis, Missouri (PRWEB) , ... December 05, ... ... people across ethnic, gender, and geographic lines. The goal of Castlewood Treatment Centers ... eating disorder treatment accessible to as many people as possible. In that ...
(Date:12/5/2016)... ... 2016 , ... Florida Hospital has named Robin McGuinness as ... brings experience in executive leadership and clinical practice, as well as a successful ... new role, that officially begins December 12, 2016, she will set the vision ...
(Date:12/5/2016)... ... , ... Sabah Shah MD, MBA has joined the Retina Group of New York ... by James M. Maisel, MD and has been providing tertiary medical and surgical retinal care ... of surpassing expectations amongst her peers. Growing up in a family of doctors, Dr. ...
(Date:12/5/2016)... ... December 05, 2016 , ... Z-Medica, LLC, a leading developer ... The American College of Surgeons (ACS) to provide basic bleeding control instructor training ... Basic” course is a pilot program that fulfills the intent of the White ...
Breaking Medicine News(10 mins):
(Date:12/5/2016)... India , December 5, 2016 According to a ... Type and by Application - Global Opportunity Analysis and Industry Forecast, 2014 - ... is expected to reach $5,255 million by 2022, growing at a CAGR of ... with more than four-fifths share. Continue Reading ... ...
(Date:12/5/2016)... 2016 Sanovas, Inc., a life science ... launch of its wholly owned subsidiary, Intubation Science, Inc., and ...   Logo - http://photos.prnewswire.com/prnh/20161202/445251LOGO   ... Sanovas, Inc. ... There are over 40 million Endotracheal ...
(Date:12/5/2016)... , Dec. 5, 2016  CVS Health, the ... has received a perfect score of 100 percent on ... year. The CEI is an annual national benchmarking survey ... LGBT equality, administered by the Human Rights Campaign Foundation. ... rich diversity that our colleagues, customers and suppliers bring ...
Breaking Medicine Technology: